基于高级MRI的阿尔茨海默氏症诊断通过集体学习技术.
Suthir Sriram1, V Nivethitha1, T P Arun Kaarthic1
1Department of Computer Science and Engineering, Amrita School of Computing, Amrita Vishwa Vidyapeetham, Chennai, India.
Scientific reports
|September 30, 2025
概括
通过MRI扫描的深度学习,提升了早期阿尔茨海默氏症的检测. 结合多个人工智能模型,在诊断疾病阶段方面实现了94.27%的准确性,有助于及时治疗.
科学领域:
- 神经成像是一种神经成像.
- 人工智能的人工智能
- 医学诊断 医学诊断 医学诊断
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,影响认知和日常功能.
- 早期诊断AD对于有效的管理和治疗策略至关重要.
- 核磁共振技术和机器学习的进步为AD检测提供了新的途径.
研究的目的:
- 评估深度学习模型,特别是卷积神经网络 (CNN) 在使用脑MRI数据诊断和分期阿尔茨海默病的有效性.
- 为了比较单个预训练模型 (ResNet50,InceptionResNetv2) 和定制训练CNN的诊断性能与组合模型方法.
主要方法:
- 利用大脑MRI数据集来训练和验证深度学习模型.
- 使用卷积神经网络 (CNN),包括ResNet50和InceptionResNetv2,用于神经成像中的模式识别.
- 开发并测试了一种混合模型,将多个CNN架构结合起来,以提高诊断准确度.
主要成果:
- 经过定制训练的CNN实现了90.76%的准确性,ResNet50达到90.27%,InceptionResNetv2单独实现了86.84%的准确性.
- 整合所有三种架构的协作模型在诊断阿尔茨海默氏症阶段时显示出94.27%的卓越准确率.
- 综合模型方法在MRI扫描中识别与阿尔茨海默氏症相关的模式方面明显优于单个模型.
结论:
- 深度学习模型,特别是结合起来时,显示出从MRI数据中对阿尔茨海默氏症的准确和自动诊断的重大前景.
- 综合模型方法为诊断阿尔茨海默病提供了增强的诊断能力,有可能改善患者的治疗结果.
- 这项研究强调了人工智能在早期发现和管理阿尔茨海默氏症等神经退行性疾病方面的潜力.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
824
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
824


